Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.
Carcinoid Syndrome
DRUG: Octreotide
Assess the effects of 1 or 2 implants on carcinoid syndrome symptoms of flushing and diarrhea, 9 months
safety and tolerability of the implants, 9 months
This study will evaluate a longer acting octreotide formulation. A subcutaneous implant at 2 doses will be evaluated for pharmacodynamics, efficacy and safety for a period of 9 months.